Sulfasalazine-induced pulmonary disease.
Sulfasalazine has been widely used in the treatment of inflammatory bowel disease. Although a high incidence of side effects has been reported, pulmonary complications are rare. The clinical, radiographic, and histological abnormalities that occurred in a patient three months after initiation of sulfasalazine are described. A review of the literature suggests that the possibility of drug-induced pulmonary disease should be considered in any patient with inflammatory bowel disease receiving treatment with sulfasalazine who develops symptoms or radiographic evidence of pulmonary disease. Transbronchial biopsy may be useful in confirming the type of pulmonary injury.
Moseley
R H
RH
Barwick
K W
KW
Dobuler
K
K
DeLuca
V A
VA
D000368:Aged; D003093:Colitis, Ulcerative / Q000188:drug therapy; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012129:Respiratory Function Tests; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D012460:Sulfasalazine; D011241:Prednisone